PPAR Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities | Zendy

Mylène Perreault | Zendy; David V. Erbe | Zendy; James F. Tobin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

PPAR Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities

Author(s) -

Mylène Perreault,

David V. Erbe,

James F. Tobin

Publication year - 2008

Publication title -

ppar research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.164

H-Index - 49

eISSN - 1687-4765

pISSN - 1687-4757

DOI - 10.1155/2008/125387

Subject(s) - obesity , medicine , weight loss , peroxisome proliferator activated receptor , intensive care medicine , bioinformatics , dieting , placebo , sibutramine , alternative medicine , pharmacology , receptor , biology , pathology

The prevalence of obesity in the USA and worldwide has reached epidemic proportions during the last two decades. Drugs currently available for the treatment of obesity provide no more than 5% placebo-adjusted weight loss and are associated with undesirable side effects. Peroxisome proliferator-activated receptor (PPAR) modulators offer potential benefits for the treatment of obesity and its associated complications but their development has been complicated by biological, technical, and regulatory challenges. Despite significant challenges, PPAR modulators are attractive targets for the treatment of obesity and could offer a viable alternative to the millions of patients who fail to lose weight following rigorous dieting and exercise protocols. In addition, PPAR modulators have the potential-added benefit of ameliorating the associated comorbidities.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research